Survival of pancreatic cancer cells lacking KRAS function
Activating mutations in the proto-oncogene KRAS are a hallmark of pancreatic ductal adenocarcinoma (PDAC), an aggressive malignancy with few effective therapeutic options. Despite efforts to develop KRAS-targeted drugs, the absolute dependence of PDAC cells on KRAS remains incompletely understood. H...
Main Authors: | Noll, Elisa M., Sprick, Martin R., Trumpp, Andreas, Muzumdar, Mandar, Chen, Pan-Yu, Dorans, Kimberly, Chung, Katherine Minjee, Bhutkar, Arjun, Hong, Erin, Jacks, Tyler E. |
---|---|
Other Authors: | Massachusetts Institute of Technology. Department of Biology |
Format: | Article |
Published: |
Nature Publishing Group
2017
|
Online Access: | http://hdl.handle.net/1721.1/112693 https://orcid.org/0000-0002-4450-7570 https://orcid.org/0000-0001-9119-8718 https://orcid.org/0000-0001-5785-8911 |
Similar Items
-
Adaptive and Reversible Resistance to Kras Inhibition in Pancreatic Cancer Cells
by: Chen, Pan-Yu, et al.
Published: (2020) -
Clonal dynamics following p53 loss of heterozygosity in Kras-driven cancers
by: Dorans, Kimberly, et al.
Published: (2017) -
Investigating the requirement of KRAS for the maintenance of pancreatic cancer
by: Chen, Pan-Yu
Published: (2016) -
KRAS and YAP1 Converge to Regulate EMT and Tumor Survival
by: Shao, Diane D., et al.
Published: (2016) -
Endocrine-Exocrine Signaling Drives Obesity-Associated Pancreatic Ductal Adenocarcinoma
by: Chung, Katherine Minjee, et al.
Published: (2021)